Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – Here’s What Happened

Pharvaris N.V. (NASDAQ:PHVS) shares saw unusually-high trading volume on Friday . Approximately 686,686 shares were traded during trading, an increase of 189% from the previous session’s volume of 237,227 shares.The stock last traded at $30.92 and had previously closed at $31.63.

Analyst Ratings Changes

PHVS has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday. Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Stock Performance

The firm has a market cap of $2.03 billion, a PE ratio of -9.78 and a beta of -2.35. The stock has a fifty day moving average price of $29.24 and a 200-day moving average price of $27.30.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts predict that Pharvaris N.V. will post -3.22 earnings per share for the current fiscal year.

Insider Activity at Pharvaris

In related news, CFO David W. Nassif sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.31, for a total transaction of $303,100.00. Following the completion of the sale, the chief financial officer directly owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. This trade represents a 7.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elisabeth Bjork sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the sale, the director directly owned 15,167 shares of the company’s stock, valued at approximately $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 209,948 shares of company stock valued at $6,268,141. 11.84% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pharvaris

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris during the 3rd quarter valued at $75,000. Barclays PLC acquired a new stake in Pharvaris during the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris during the 4th quarter valued at $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.